Pharma IP Summit: ‘Law firms should not act like law firms’
In-house counsel from Bayer, Mylan and Sun Pharmaceutical share outside counsel preferences and litigation strategies
Speaking at the 4th China Pharma IP Summit in Shanghai, in-house counsel from innovator drug companies and generics argued that having a fair price and ensuring that outside counsel offer value in specific areas are pivotal.
Looking at the thought...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.